Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET
Company Participants
Christine Chiou - Senior Vice President-Investor Relations
Samantha Du - Founder, Chairperson & Chief Executive Officer
Josh Smiley - President & Chief Operating Officer
Rafael Amado - President and Head-Global Oncology Research & Development
Harald Reinhart - President and Head-Global Development, Neuroscience, Autoimmune & Infectious Diseases
Yajing Chen - Chief Financial Officer
Jonathan Wang - Chief Business Officer
Conference Call Participants
Jiajun Wen - Jefferies
Anupam Rama - JPMorgan
Louise Chen - Cantor
Yigal Nochomovitz - Citigroup
Linhai Zhao - Goldman Sachs
Matt Cowper - Leerink Partners
Jack Lin - Morgan Stanley
Operator
Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, today's call is being recorded.
It's now my pleasure to turn the floor over to Christine Chiou, Senior Vice President of Investor Relations. Please go ahead.
Christine Chiou
Thank you, operator. Good morning, good evening, and welcome, everyone. Zai Lab's full year 2023 earnings call. Today's call will be led by Dr. Samantha Du, Zai Lab’s Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Amado, President and Head of Global Oncology Research and Development, Dr. Harald Reinhart, President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases and Dr. Yajing Chen, Chief Financial Officer. Jonathan Wang, our Chief Business Officer will also be available to answer questions during the Q&A portion of the call.
As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectation. These statements are subject to numerous risks and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings.
We will also refer to product revenue growth rate on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on February 27, 2024 for additional information on this non-GAAP financial measure.
At this time, it is my pleasure to turn the call over to Dr. Samantha Du.
Samantha Du
Thank you, Christine. In 2023, we had another year of significant achievements for Zai Lab. We grew our top line by 31% on a constant exchange rate basis. We progressed several key late-stage programs. We added new global assets into our pipeline. Today, we're in a fundamentally stronger position than we have ever been, with a growing base of revenues, a path to profitability and a strong balance sheet with over US$800 million in cash.